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Abstract 
Considerable progress has been made in non-animal methods and approaches for skin sensitisation assessment 
since the publication in 2013 of the EURL ECVAM strategy for this endpoint. This report illustrates EURL ECVAM 
views on the regulatory use of individual test methods, including two in vitro methods peer reviewed by ESAC, 
the LuSens and the U-SENS™ and on defined approaches and provides EURL ECVAM recommendations on 
future work to be undertaken in the area. 
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Executive summary 
Considerable progress has been made in non-animal methods and approaches for skin 
sensitisation assessment since the publication of the EURL ECVAM strategy document for 
this endpoint in 2013. At the OECD level, three EURL ECVAM validated and/or peer 
reviewed non-animal methods addressing Key Events (KE) of the skin sensitisation 
Adverse Outcome Pathway (AOP) have been adopted as OECD Test Guideline (TG) 442C 
(Direct Peptide Reactivity Assay, DPRA); OECD TG 442D (KeratinoSens™) and, OECD TG 
442E (human Cell Line Activation Test, h-CLAT). Other in vitro (cell-based) methods, the 
U937 Cell Line Activation Test (U-SENS™) and the IL-8 Luc assay are at an advanced 
stage in the regulatory adoption process whereas the LuSens, the SENS-IS and the 
Genomic Allergic Detection Test (GARD) are under consideration by the OECD for the 
development of the respective TGs. Among these methods the LuSens and U-SENS™ 
underwent independent peer review by the EURL ECVAM Scientific Advisory Committee 
(ESAC). The outcome of the ESAC peer review was considered by EURL ECVAM when 
issuing its recommendation on both methods. 
Various Defined Approaches (DAs), integrating non-animal data generated with the 
regulatory adopted methods, have been proposed as valid components of Integrated 
Approaches to Testing and Assessment (IATA) and documented in OECD Guidance 
Document (GD) 256 using harmonised templates for their reporting (provided in OECD 
GD 255). This progress was the driver of the revision of the REACH information 
requirements for the skin sensitisation endpoint, with in chemico and in vitro methods 
becoming the default route, and of the update of the REACH Guidance on Information 
Requirements and Chemical Safety Assessment for Skin and Respiratory Sensitisation 
published by ECHA. 
 
This document provides EURL ECVAM views on the regulatory use of non-animal 
approaches for skin sensitisation and delivers the following key EURL ECVAM 
recommendations: 
 
• The qualitative and quantitative mechanistic information generated by the in 
chemico and in vitro methods adopted by the OECD should be used, together with 
other relevant information, within DAs and IATA for assessing skin sensitisation 
hazard and for hazard classification purposes; 
 
• Predictions generated with valid DAs1 should be used, where applicable and 
adequate, instead of LLNA data or in conjunction with such data if they already 
exist, in the context of IATA for assessing skin sensitisation hazard and for hazard 
classification purposes; 
 
• New DAs used for regulatory purposes should be properly documented using the 
templates provided in OECD GD 255; 
 
• To promote international applicability and acceptance of alternative non-animal 
approaches to skin sensitisation, future work should focus on the definition of 
internationally agreed standards (e.g. OECD TGs) for DAs and individual test 
methods that provide equivalent or better level of information than the current 
animal tests for skin sensitisation;  
 
• The LuSens and U-SENS™ methods, that underwent ESAC peer-review in 2016, 
should be used as valid scientific methods for generating information respectively 
on KE2 and KE3 of the skin sensitisation AOP to be considered together with other 
relevant information in the context of DAs and IATA. Inclusion of the LuSens as 
similar method to the KeratinoSens™ in OECD TG 442D and development of an 
OECD TG on the U-SENS™ is fully supported. 
                                           
1 Examples of DAs which are considered for further evaluation are reported in Annex I to OECD GD 256. 
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1. Introduction 
Skin sensitisation is the regulatory endpoint aiming at the identification of chemicals able 
to elicit an allergic response in susceptible individuals. Following repeated exposure to a 
sensitising agent, the adverse health effect of allergic contact dermatitis (ACD) may be 
provoked. Thus the development of ACD is characterised by two distinct phases: a) the 
induction of specialised immunological memory following the initial exposure to an 
allergen, called sensitisation and b) elicitation of the clinical allergic response following 
subsequent exposure to the allergen. Skin sensitisation assessment is an important 
component of the safety evaluation of chemicals. 
In 2013 EURL ECVAM undertook an analysis of the standard regulatory requirements for 
skin sensitisation within pieces of EU chemicals legislation. This analysis, reported in the 
EURL ECVAM skin sensitisation strategy document (EURL ECVAM, 2013a), clearly 
indicated that the availability of non-animal approaches capable of identifying skin 
sensitisation hazard and generating information that would satisfy chemicals' 
classification needs (i.e. potency sub-categorisation) would have the biggest impact in 
terms of reduction in total number of animal used in the area.  
The EURL ECVAM strategy document also outlined the actions EURL ECVAM planned to 
undertake in the short (2013-2014), medium (2014-2015) and long term in order to 
advance progress in the area:  a) to finalise the validation and peer review of non-animal 
test methods for skin sensitisation and lead activities for their regulatory adoption b) to 
develop non-animal testing strategies suitable for hazard identification and potency sub-
categorisation of sensitising chemicals and c) to take a leading role at the OECD in the 
development of Test Guidelines (TG) and Guidance Documents (GD) that would facilitate 
a globally harmonised approach to skin sensitisation assessment. 
Despite the fact that in the last decade regulations in the cosmetics and chemicals 
sectors have provided a strong impetus to assess potential toxic effects of chemicals with 
non-animal methods, at the time of writing of the EURL ECVAM skin sensitisation 
strategy the assessment of the skin sensitisation potential of chemicals still relied on the 
use of animal tests (i.e. mainly the Local Lymph Node Assay or LLNA) since no regulatory 
adopted non-animal methods were available for the purpose. Nevertheless, in chemico 
and in vitro (cell-based) methods, addressing mechanisms described under the first three 
Key Events (KEs) of the skin sensitisation Adverse Outcome Pathway (AOP) initiated by 
covalent binding to proteins (OECD 2012), were under development by industry and 
academia. 
Three of these methods, namely, the Direct Peptide Reactivity Assay (DPRA), 
KeratinoSens™ and the human Cell Line Activation Test (h-CLAT) were being formally 
evaluated by EURL ECVAM through validation and/or independent peer review by the 
EURL ECVAM Scientific Advisory Committee (ESAC). Subsequent to the ESAC peer review 
and the publication of the EURL ECVAM Recommendation on the three methods (EURL 
ECVAM 2013b; 2014; 2015), EURL ECVAM took a leading role on behalf of the EU at the 
OECD in the development of the corresponding TGs. In 2015 the OECD adopted the 
DPRA and the KeratinoSens™ as TGs 442C and 442D respectively (OECD 2015a; 2015b) 
and in 2016 the h-CLAT as TG 442E (OECD 2016a).   
In addition to the adopted test methods, knowledge of the skin sensitisation pathway has 
prompted the development of a wide range of other alternative methods (in silico, in 
chemico, in vitro), addressing specific KEs of the AOP (OECD 2012). Some of these non-
animal tests: the SENS-IS (Cottez et al., 2016) and the LuSens (Ramirez et al., 2016), a 
similar method to the KeratinoSens™, addressing KE2, the U-SENS™ (Piroird et. al. 
2015; Alépée et al., 2015), the IL-8 Luc Assay (Kimura et al., 2015) and the GARD 
(Johansson et al., 2013; 2014), the latter three all addressing mechanisms under KE3 of 
the skin sensitisation AOP, have been included in the OECD TG programme. The U-
SENS™ and the LuSens underwent an industry-led validation study and have recently 
been peer-reviewed by the ESAC (EURL ECVAM Scientific Advisory Committee 2016a; 
2016b). A description of the U-SENS™ and the LuSens including the EURL ECVAM 
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Recommendations on both methods are provided under the respective sections at the 
end of this document. 
Information generated by these methods can contribute to informing regulatory skin 
sensitisation assessment and hazard categorisation (e.g. according to the United Nations 
Globally Harmonised System of Classification and Labelling of Chemicals, GHS, Category 
1, 1A and 1B) when used in combination with other relevant evidence, i.e. in the context 
of Integrated Approaches to Testing and Assessment (IATA) and Defined Approaches 
(DAs) to testing and assessment (OECD 2016b).  
DAs are based on a fixed set of information sources and a fixed data interpretation 
procedure (DIP) to convert inputs from the different information sources into a prediction 
(OECD, 2016b) and are therefore standardised both in relation to the set of information 
sources used and in the DIP applied to the data to derive predictions intended to be used 
within IATA (OECD, 2016b). In contrast, the assessment process within IATA cannot be 
standardised since it is always underpinned by a weight of evidence approach (judgment 
–based approach) (OECD, 2017).  
Various DAs for skin sensitisation which integrate data from in silico, in chemico and in 
vitro methods have been proposed in the past few years. Generally, they are designed to 
enable the use of mechanistic data from these methods together with other relevant 
information to predict responses in the LLNA.   
In 2013, mindful of the several DAs for skin sensitisation under development, EURL 
ECVAM took a leading role for the EU at the OECD in the definition of guidance on the 
reporting of such approaches and proposed to the OECD Task Force on Hazard 
Assessment (TFHA), now the Working Party on Hazard Assessment (WPHA), to set up an 
expert group charged with the development of such guidance with the aim to bring to 
regulatory attention as many approaches as possible. 
Discussions within the OECD expert group led to the conclusion that at that point in time, 
merging or harmonisation of such approaches into a single solution that would satisfy all 
possible regulatory needs was impossible. Instead, the diverse structures and DIPs 
underlying the different DAs was acknowledged as providing flexibility in the choice of the 
most appropriate approach to satisfy a specific need. It was also decided that priority 
should be given to the development of guidance to ensure a harmonised reporting of DAs 
since when used as components within IATA this would ultimately facilitate the 
application and evaluation of the IATA themselves for regulatory purposes. 
In June 2016 the OECD TFHA endorsed two GD on the reporting of DAs. The OECD GD 
255 (OECD, 2016b) provides a set of principles for the reporting of DAs and provides 
reporting templates to enable their structured documentation. Beside other elements, 
emphasis is put in the templates on the proper reporting of the limitations in the 
application of the DA, on their predictive performance and on the sources of uncertainty 
that may impact on the final prediction. The OECD GD 256 (OECD, 2016c; OECD 2016d; 
OECD 2016e) exemplifies how the reporting templates have been used to document a 
number of DAs developed in the area of skin sensitisation. It is envisaged that these 
templates will be applied to document DAs developed in other areas of toxicology. 
The international regulatory adoption of the first three non-animal test methods for skin 
sensitisation and proposals on how to use these methods in combination within DAs, 
paved the way in the EU to a substantial revision of the information requirements for skin 
sensitisation as laid down in Annex VII of the REACH regulation (EC, 2006; EU, 2016). In 
chemico and in vitro test methods have become the default requirement and the in vivo 
methods can now only be used if the non-animal tests are shown to be unsuitable for 
testing a specific substance or cannot be used for classification and risk assessment (EU, 
2016). The revised provisions also foresee consideration of whether a substance can be 
presumed to have the potential to induce significant sensitisation in humans (i.e. GHS 
Category 1A). The amended requirements, which entered into force in October 2016, will 
therefore have a substantial impact in replacing and reducing animal testing in view of 
the 2018 REACH registration deadline. Advances in the area have also prompted the 
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revision of the European Chemicals Agency's (ECHA) guidance to industry on Information 
Requirements and Chemical Safety Assessment (Chapter R 7.a, section R.7.3 Skin 
sensitisation; ECHA, 2016). The revised ECHA draft guidance describes the scope and 
limitations of the adopted alternative methods to help registrants using them to fulfil the 
information requirements under REACH. In addition, it proposes a testing and 
assessment strategy for skin sensitisation assessment which also illustrates how 
information on the first three key events of the skin sensitisation AOP (i.e. information 
generated with the validated alternative methods) can be considered in a weight-of-
evidence (WoE) approach. Although the guidance recommends the testing and 
assessment strategy to be followed, it acknowledges that other approaches may be more 
appropriate depending on the specific case.  
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2. Use of non-animal approaches 
The in chemico and in vitro test methods recently adopted by the OECD address the first 
three KEs of the skin sensitisation AOP (OECD 2012). The DPRA (TG 442C; OECD 2015a) 
provides information on a chemical's reactivity towards peptides, considered to model the 
molecular initiating event (MIE) or KE1 within the skin sensitisation AOP. The 
KeratinoSens™ (TG 442D; OECD 2015b) detects activation of a relevant pathway (the 
Keap1/antioxidant/electrophile response element (ARE)-dependent pathway) in human-
derived keratinocytes providing information on KE2 and h-CLAT (TG 442E; OECD 2016a) 
addresses KE3 by measuring, in a human monocytic leukemia cell line, the up-regulation 
of markers of dendritic cell (DC) activation following exposure to sensitising agents. 
Based on the data generated during the validation studies and historical evidence, the 
three OECD-adopted test methods have been shown to be transferable to laboratories 
that have sufficient experience in the techniques involved and to be reproducible for 
positive/negative predictions in the order of 80-85%. In addition, they demonstrated 
considerable accuracy, of about 80%, in predicting LLNA responses despite the fact that 
they are not meant to be used as stand-alone replacement methods. Moreover, they 
have been shown in recent analyses to have the ability to correctly detect as positives 
the majority of chemicals that need to be air oxidised (pre-haptens) or enzymatically 
transformed (pro-haptens) to act as sensitisers (Casati et al., 2016; Urbisch et al., 2016; 
Patlewicz et al., 2016).  
Besides the qualitative information (positive/negative predictions), DPRA, KeratinoSens™ 
and h-CLAT also provide quantitative readouts that can inform hazard classification (i.e. 
potency categorisation). Nevertheless, the three methods cannot be used in isolation for 
potency categorisation or to predict potency for safety assessment.  
EURL ECVAM recommends using the qualitative and quantitative mechanistic 
information generated by the OECD adopted methods, together with other 
relevant information, in the context of DAs and IATA for assessing skin 
sensitisation hazard and for hazard classification purposes.  
In the past few years advancements have also been made in the integration of data from 
different non-animal tests in the context of DAs to improve accuracy in predictions with 
respect to the individual methods. Twelve of these DAs are documented in Annex I to 
OECD GD 256 (OECD, 2016d). These DAs are based on the use of information sources 
addressing key mechanisms/events of the skin sensitisation AOP and make use of a 
variety of specific methodologies, i.e. DIP, for converting the input data into a final 
prediction.  
The documented DAs provide a good overview of the different set of information sources 
and DIP that can be used for skin sensitisation hazard assessment and/or classification. 
The DIP can range from very simple rule-based sequential decision steps to mathematical 
and statistical approaches. Besides those reported in Annex I to OECD GD 256 (OECD, 
2016d), other DAs have been documented in the scientific literature (e.g. Luechtefeld et 
al., 2015; Macmillan et al., 2016; Strickland et al., 2017; Zang et al., 2017) and recently 
reviewed by Ezendam et al. (2016). 
Table 1 provides an overview of the DAs in relation to their proposed use, AOP coverage, 
type of information sources used within, number of chemicals tested and predictive 
performances. Note that the information provided is meant to give a flavour of each DA 
and does not allow a comprehensive understanding of the DA structure and actual 
performance. The reader should refer to OECD GD 256 (OECD 2016c) and its two 
annexes (OECD 2016d; 2016e) for a detailed description of the different DAs. In 
addition, it is beyond the scope of this document to offer any detailed comparison of the 
different DAs especially in relation to their predictive performance knowing that 
performance statistics are very much dependent on the dataset used which differs among 
the reported DAs. 
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Nevertheless, from the information summarised in Table 1 some general observations 
can be made:  
1) All DAs make use of mechanistic data addressing one or more key events (KE) of the 
skin sensitisation AOP (OECD 2012). Despite non-animal experimental data on KE4 (T 
cell priming and proliferation) being included in any of the DAs due to the lack of 
standardised alternative methods addressing this KE, the different DAs already show a 
high level of accuracy in predicting binary (i.e. sensitiser/non-sensitiser) LLNA 
classification.  
2) Besides that derived from validated and regulatory adopted methods, other relevant 
information such as physicochemical properties and in silico predictions, contribute to 
skin sensitisation hazard assessment and classification. 
3) Information on KE1 (i.e. the MIE in the skin sensitisation AOP) is used in all DAs 
(either derived with in silico models and/or with in chemico, in vitro methods) and in 
some cases reactivity information has proven by the underlying analyses to have the 
highest power in discriminating between sensitising and non-sensitising chemicals (e.g. 
Natsch et al., 2015; Asturiol et al., 2016). 
4) All of the DAs make use of cell-based assays and/or in silico descriptors that account 
for skin metabolism and autoxidation processes. In fact, as detailed in Annex I to OECD 
GD 256 (OECD, 2016d), the number of pre- and pro-haptens erroneously classified as 
being non-sensitisers is generally limited. 
5) The majority of the DAs have been developed/tested with a substantial number of 
chemicals (in certain cases more than 200) for which in vivo skin sensitisation data are 
available, therefore it is likely that their domain of applicability covers the main reaction 
mechanisms relevant to skin sensitisation. 
6) The accuracy of the different DAs specifically designed to predict binary (i.e. 
sensitiser/non-sensitiser) LLNA classifications is high and in the range of 79-93% (with 
sensitivity in the range of 79-98% and specificity in the range of 72-94%).  
7) Where an evaluation of the predictive capacity against human data was performed, 
this shows that the DAs tend to predict human responses more accurately than the 
animal model (LLNA) does (e.g. Urbisch et al., 2015; Asturiol et al., 2016; Strickland at 
al., 2017; Zang et al., 2017). 
8) Six of the DAs are designed for potency assessment. When considering their accuracy 
in predicting sensitisation potency, an important aspect to consider is the variability of 
the reference in vivo data. Consistent with what was already known about the variability 
of the LLNA (e.g. ICCVAM 2011), recent analyses have confirmed that this is far from 
being negligible (Hoffmann, 2015; Dumont et al., 2016) making it difficult to assign a 
chemical to a specific potency class with sufficient confidence on the basis of a single 
LLNA study result.  
In light of the above, it is evident that some of the DAs developed in the area of skin 
sensitisation have comparable performance to the LLNA for the identification of skin 
sensitisation hazard. Moreover, some of them appear to be more accurate than the LLNA 
in predicting hazard responses in humans. Although it is recognised that further work is 
needed to achieve a more detailed definition of the relative potency of identified skin 
sensitising chemicals for risk assessment purposes, the DAs summarised in Table 1 
already provide useful information for the purpose of classification and labelling. It is 
acknowledged that the current GHS criteria for hazard classification are not based on in 
vitro data. However work has been initiated at GHS level on how to make use of non-
animal test methods for the purpose of hazard classification. 
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EURL ECVAM recommends that the predictions generated using valid DAs2 be 
used, where applicable and adequate, instead of LLNA data or in conjunction 
with such data if they already exist, in the context of IATA for assessing skin 
sensitisation hazard and for hazard classification purposes. 
EURL ECVAM recommends that new DAs used for regulatory purposes be 
properly documented using the templates provided in OECD GD 255. 
 
                                           
2   Examples of DAs which are considered for further evaluation are reported in Annex I to OECD GD 256 
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3. Future developments  
Table 1 indicates that some of the DAs have comparable or even better performance than 
the LLNA for skin sensitisation hazard assessment and classification. It is nevertheless 
recognised that additional work is needed to refine sensitisation potency prediction for 
the purpose of risk assessment. At the international level, progress was made to 
guarantee harmonised reporting of DAs in view of facilitating their regulatory application. 
However, harmonised reporting is not sufficient to guarantee their effective 
implementation and acceptance of the DAs' predictions by different jurisdictions and 
regions. 
EURL ECVAM recommends that future work should focus on the definition of 
internationally agreed standards (e.g. OECD TGs) for DAs and individual test 
methods that provide equivalent or better level of information than the current 
animal tests for skin sensitisation. 
To this end, the European Commission, United States and Canada have submitted a 
project proposal to the OECD Test Guidelines Programme for the development of a 
performance-based test guideline (PBTG) for DAs and test methods for skin sensitisation. 
According to the proposal work should be undertaken to develop assessment criteria to 
objectively and systematically evaluate the DAs reported in Annex I to OECD GD 256 as 
well as other candidate DAs and upcoming individual test methods. Such assessment 
criteria should be informed by a comprehensive understanding of the performance of the 
LLNA in terms of reproducibility and relevance in predicting human responses. 
As part of the previous OECD activities on the documentation of DAs (OECD 2016b, 
2016c), emphasis has been given to systematically report the possible sources of 
uncertainty associated with the application of a specific DA. For example, uncertainties 
can be associated with the structure of the DA itself, the information sources used within 
(e.g. variability of the input data) and the in vivo (animal and/or human) benchmark 
data used to assess the performance of the DA. In fact the predictive performance of the 
DAs listed in Table 1, including those proposed for potency categorisation, has been 
evaluated using as benchmark data individual LLNA predictions and potency estimates 
(i.e. EC3 values). Thus the calibration of the DIP associated with each DA did not take 
into account either the variability of the animal test or the variability associated with the 
model input parameters (e.g. non-animal data). The impact of the combined effect of 
these sources of uncertainties on the final DA prediction should be further characterised 
as part of future activities on the evaluation of DAs. 
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4. The LuSens test method 
The LuSens is an in vitro test method proposed to contribute to the assessment of the 
skin sensitisation potential of chemicals when used in conjunction with other information 
(i.e. in the context of DAs and IATA).  
The method quantifies luciferase gene induction as a measure of the activation of the 
Keap1/antioxidant/electrophile response element (ARE)-dependent pathway in a 
keratinocyte cell line stably transfected with a selectable plasmid. The LuSens is 
addressing the mechanism of induction of cyto-protective pathways in keratinocytes, 
covered by KE2 in the skin sensitisation AOP (OECD, 2012). The LuSens method is 
considered similar to the KeratinoSensTM for which an OECD TG is available (OECD TG 
442D) (OECD, 2015b) supplemented by “Performance standards (PS) for assessment of 
proposed similar or modified in vitro skin sensitisation ARENrf2 luciferase test methods” 
(OECD, 2015c).  
The LuSens underwent an industry-led PS-based validation study involving four 
laboratories and conducted to fulfil the requirements detailed in the OECD PS for 
demonstrating comparable performance to that of the validated KeratinoSens™ and 
adherence to the essential test methods components that would assure similarity with 
the validated reference method. 
The validation study demonstrated that the method is easily transferable to laboratories 
experienced in cell culture techniques. The within-laboratory reproducibility (WLR) and 
the between-laboratory reproducibility (BLR), as calculated on the basis of concordant 
classifications for the chemicals tested (n=12 for WLR and n=20 for BLR) was 100%. The 
LuSens also complied with the performance standards requirements for accuracy ≥ 80% 
(LuSens 85%) and sensitivity ≥ 80% (LuSens 92%) but not with the one for specificity ≥ 
80% (LuSens 75%). Potential differences between the LuSens and the KeratinoSens™ 
assays were only observed for methyl salicylate and eugenol, which resulted in 
apparently higher sensitivity and lower specificity. 
The ESAC Opinion on the method, delivered in June 2016 (EURL ECVAM Scientific 
Advisory Committee, 2016a), highlighted the fact that the two substances giving 
different results in the two methods are borderline substances (i.e. give both positive and 
negative predictions in repeated runs in several methods, including LuSens, 
KeratinoSens™, DPRA, h-CLAT and also in the LLNA and humans).  
EURL ECVAM recommends the use of the LuSens as a valid scientific method for 
generating information on KE2 of the skin sensitisation AOP to be used together 
with other relevant information in the context of DAs and IATA and fully 
supports the inclusion of the method into OECD TG 442D. 
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5. The U-Sens™ test method 
The U-SENSTM is an in vitro test method proposed to contribute to the assessment of the 
skin sensitisation potential of chemicals when used in conjunction with other information 
(i.e. in the context of DAs and IATA).  
The test method is based on the quantitative cytofluorimetric analysis of the induction of 
the CD86 protein marker in U937 cells (a cell line established from a diffuse histiocytic 
lymphoma) after 45h exposure to the test chemical. The test method is proposed to 
address KE3 (DC activation) of the AOP (OECD, 2012). The U937 cells are human 
myeloid cells used as a surrogate model for DC. Activated upon contact with skin 
sensitizers, they increase their CD86 expression. The induction of the CD86 membrane 
protein following exposure to skin sensitisers is one of the biomarkers indicating 
activation of DC that is most frequently used in in vitro assays. The U-SENS™ is similar 
to the h-CLAT (OECD, 2016a) although the latter is based on the measure of expression 
levels of both CD86 and CD54 cell surface markers in THP-1 cells. 
The U-SENSTM underwent an industry-led validation study designed primarily to address 
the reproducibility of the method (WLR and BLR). The WLR assessed in four laboratories 
on the basis of concordant classifications for 15 chemicals was 73%, 93%, 100% and 
100% respectively (average 91.7%) with the lowest reproducibility was observed in the 
laboratory less familiar with the use of the U-SENSTM method indicating that the method 
may require expertise and time for proper implementation. The between-laboratory 
reproducibility was approximately 84% (n=38). 
The accuracy of the method in discriminating between sensitisers and non sensitisers on 
the basis of LLNA classifications was calculated to be 93% (sensitivity 97%, specificity 
89%) with the chemical tested in the validation study (n=38). In addition, performance 
values for a larger set of 166 substances tested in house were provided indicating an 
accuracy of 85% (sensitivity 95% and specificity 65%) when evaluated against LLNA 
data. When evaluated against human data (n=101) the U-SENSTM showed an accuracy 
of 83% (sensitivity 95% and specificity 59%). 
The limitations of the U-SENSTM are likely to be very similar to other submerged cell 
culture assays (e.g. h-CLAT, KeratinoSens). Potential issues may be encountered with 
substances of low solubility or low stability in an aqueous environment, fluorescent 
substances interfering with flow cytometry analysis, pro-haptens and volatile substances 
and substances disrupting cell membranes. Pre-haptens included in the validation 
chemicals set were correctly detected by the USENSTM. 
The ESAC Opinion on the method, delivered in June 2016 (EURL ECVAM Scientific 
Advisory Committee, 2016b), indicated that the application of six rules to the prediction 
model to resolve inconclusive results increases the complexity of the method without 
adding to its predictive performance since in most cases the six rules appears to convert 
inconclusive results into positive results. This suggestion has been taken into account by 
the test developer through a revision of the protocol and a supporting analysis of the 
validation study data and historical data showing that the elimination of the six rules 
does not impact on the test method's performance. 
EURL ECVAM recommends the use of the U-SENS™ as a valid scientific method 
for generating information on KE3 of the skin sensitisation AOP to be used 
together with other relevant information in the context of DAs and IATA and 
fully supports the development of an OECD TG on the method. 
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Table 1: Overview of the Defined Approaches documented in Annex I to OECD GD 256 
 
 
  
 Defined Approach Proposed use AOP KEs 
addressed
3
 
Information sources 
used
4
 
DIP Number of 
chemicals 
tested 
 
Predictive 
capacity 
parameters (%) 
evaluated 
against LLNA 
and/or human 
responses
5
 
Comments 
1 AOP –based "2 out of 
3" weight of evidence 
/ integrated testing 
strategy ("2 out of 3 – 
Sens ITS") approach to 
skin hazard 
identification (BASF) 
Hazard 
identification 
1,2,3 OECD TG 442C (KE1) 
OECD TG 442D or 
LuSens (KE2) 
mMUSST or OECD TG 
442E (KE3) 
Integrated Testing 
Strategy (ITS) in 
which concordant 
results for two KEs 
drive the prediction  
213  
(151 S
6
) (62 NS
6
) 
 
Against LLNA 
(n=126-180): 
Accuracy 79-84 
Sensitivity 79-84 
Specificity 72-84  
 
Against human 
(n=75-101): 
Accuracy 88-91 
Sensitivity 84-90 
Specificity 89-100 
 
 
                                           
3 The Key Events (KE) reported in the column does not necessary imply that all of them are addressed each time a substance is tested with the DA 
4 The information sources are not necessarily listed in the table in the order they are used within the DAs 
5 Predictive capacity parameters are those documented in Annex I to OECD GD 256 (OECD, 2016d) and, where possible, are presented as ranges when more than one value 
is reported (e.g. in case these have been calculated using different subsets of data) 
6 S=sensitiser, NS= non-sensitiser on the basis of the reference in vivo data 
*Values calculated by EURL ECVAM 
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2 Sequential Testing 
Strategy (STS) for 
hazard identification 
of skin sensitisers 
(RIVM) 
Hazard 
identification 
1,2,3,4 OECD TG 442C (KE1) 
OECD TG 442D and 
HaCaT gene signature 
(KE2) 
OECD TG 442E (KE3) 
Bayesian QSAR 
approach (MultiCASE, 
CAESAR, DEREK and 
OECD QSAR Toolbox) 
(KE4) 
 
Sequential Testing 
Strategy (TST) in 
which decision 
criteria are applied 
after each tier  
41  
(27 S) (14 NS) 
Against human: 
Accuracy 95 
Sensitivity 96 
Specificity 93  
 
LLNA against 
human 
Accuracy 78 
Sensitivity 93 
Specificity 64  
 
 
 
 
 
 
Performance of 
the LLNA in 
predicting human 
responses for the 
same set of 
chemicals, 
as reported in van 
der Veen et al. 
(2014). 
3 A non-testing Pipeline 
approach for skin 
sensitisation (G. 
Patlewicz) 
Primarily 
hazard 
identification. 
In certain cases 
allows sub-
categorisation 
of sensitisers 
into GHS 
subcategories 
1A and 1B 
1,2,3,4,AO 
 
Various physicochemical 
properties 
Various in silico 
simulators for abiotic or 
enzymatic activation 
Various in silico 
methods (KE1, KE2 and 
KE4) 
TG 442C and 
glutathione depletion 
assay (KE1) 
OECD TG 442D (KE2) 
OECD TG 442E and U-
SENS™ (KE3) 
OECD TG 429 (KE4) 
OECD TG 406 (AO) 
Others 
  
 
Weight-of-evidence 100 
(55 S) (45 NS) 
Against LLNA, 
GPMT, Buehler 
test: 
Accuracy 88 
Sensitivity 89 
Specificity 86  
 
This approach 
represents an 
IATA workflow 
rather than a DA.  
It was used to 
show that the 
template provided 
in OECD GD 255 is 
flexible enough to 
be used to 
document IATA 
besides DAs. 
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4 Stacking meta-model 
for skin sensitisation 
hazard identification 
(L'Oréal) 
Hazard 
identification 
1,2,3 Various physicochemical 
properties 
Various in silico  
methods and OECD TG 
442C (KE1) 
OECD TG 442D (KE2) 
U-SENS™ (KE3) 
Meta-model 
stacking five 
different statistical 
methods (Boosting, 
Naïve Bayes, 
Support Vector 
Machine (SVM), 
Sparse PLS-DA and 
Expert Scoring). The 
model provides a 
probabilistic output 
165  
113 training set 
(66 S) (47 NS) 
52 test set 
(31 S) (21 NS) 
Against LLNA for 
training set: 
Accuracy  93 
Sensitivity 95 
Specificity 90 
 
Against LLNA for 
test set: 
Accuracy  92 
Sensitivity 93 
Specificity 90 
Overall accuracy 
values not 
reported. 
5 Integrated decision 
strategy for skin 
sensitisation hazard 
(ICCVAM) 
Hazard 
identification 
3,4,AO Various physicochemical 
properties 
OECD TG 442E (KE3) 
OECD Toolbox (KE4, AO) 
 
Support vector 
machine 
120  
(87 S) (33 NS) 
 
 
 
  
Against LLNA: 
Accuracy  88 
Sensitivity 85 
Specificity 94 
 
 
Accuracy values 
for training and 
test set reported 
in the Annex I to 
OECD GD 256. 
6 Classification 
consensus model of 
decision trees based 
on in silico descriptors 
to predict skin 
sensitisation hazard 
(EC- JRC) 
Hazard 
identification 
1 Various in silico 
descriptors generated 
with TIMES-SS (KE1) and 
DRAGON software 
packages  
Consensus model of 
two decision trees 
269 
(170 S) (99 NS) 
Against LLNA 
(n=269): 
Accuracy 93 
Sensitivity 98 
Specificity 85  
 
Against human 
(n=99):  
Accuracy 81 
Sensitivity 90 
Specificity 64 
Accuracy values 
for training and 
test set reported 
Annex I to OECD 
GD 256. 
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7 Sensitizer potency 
prediction based on 
Key event 1 + 2: 
Combination of kinetic 
peptide reactivity data 
and KeratinoSens™ 
data (Givaudan) 
Hazard 
identification 
Prediction of a 
continuous 
likely LLNA or 
human potency 
value 
Potency sub-
categorisation 
in the two GHS 
potency classes 
(1A and 1B) 
 
 
1,2 Various physicochemical 
properties 
TIMES-SS and Cor1C420-
assay (KE1) 
OECD TG 442D (KE2) 
Reactivity domain-
based regression 
equations 
 
Global regression 
equation for 
chemicals that 
cannot be assigned 
to a specific domain 
244 
(133 S) (111 NS) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Human GHS 
class 1B (44 S) 
Human GHS 
class 1A  
(27 S) 
Against LLNA for 
binary 
classification: 
Accuracy
  
83* 
Sensitivity 89* 
Specificity 75* 
 
Against LLNA GHS 
potency classes 
(NS, 1B, 1A) 
Accuracy:  
Overall for 3 
classes 75 
NS   76* 
1B   77* 
1A   70* 
 
 
a) Predicted by in 
vitro data: 
1B 55   
1A 70 
 
b) Predicted by 
LLNA data: 
1B 72   
1A 52 
 
 
 
 
 
The accuracy 
values reported 
are calculated 
combining results 
from the global 
and domain 
models. 
 
 
 
 
 
 
 
 
 
 
 
Classifications 
derived by 
estimating human 
DSA05 values 
(induction dose 
per skin area, in 
μg/cm2, in a 
human repeat-
insult patch test 
or human 
maximization test 
that produces a 
positive response 
in 5% of the 
tested population 
using a) in vitro 
data and b) LLNA 
data. 
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8 The artificial neural 
network model for 
predicting LLNA EC3 
(Shiseido) 
Hazard 
identification 
potency sub-
categorisation 
in 
3 potency 
classes: non-
sensitisers (N), 
combined 
weak and 
moderate (M), 
combined 
strong (S) and 
extreme (E) 
sensitisers 
1,2,3 Log P 
cell-surface thiol test 
(SH test) (KE1) 
Antioxidant Response 
Element (ARE) assay 
(KE2) 
OECD TG 442E (KE3) 
Artificial neural 
network 
62 
(48 S) (14 NS) 
Against  3 LLNA 
potency classes 
(NS, W/M, S/E) 
Accuracy:  
Overall for 3 
classes 79 
NS 64* 
W/M   93* 
S/E   67* 
 
 
 
9 Sensitizer potency 
prediction based on 
Key event 1+2+3: 
Bayesian Network 
ITS/DS for hazard and 
potency identification 
of skin sensitizers 
(P&G) 
LLNA potency 
probabilistic 
distribution 
(pEC3), for  4 
potency 
classes: non-
sensitisers (N), 
weak (W), 
moderate (M), 
and combined 
strong (S) and 
extreme (E) 
sensitisers 
1,2,3 Various parameters for 
bioavailability 
In silico simulators for 
abiotic or enzymatic 
activation (TIMES) 
TIMES-SS and OECD TG 
442C (KE1) 
OECD TG 442D (KE2) 
OECD TG 442E (KE3) 
Bayesian Network, 
the model provides 
a prediction with 
either all or partial 
data inputs 
207 
(154 S) (53 NS) 
Against LLNA for 
binary 
classification: 
Accuracy 96 
 
Against 4 LLNA 
potency classes 
(NS, W, M, S/E): 
Accuracy:  
Overall  74-89 
NS  87-100 
W   83-90 
M   45-75 
S/E  60-87 
The accuracy 
reported is 
calculated for the 
test set and 
considering data 
inputs and 
omission of each 
one of the KE 
assays. 
 
Potency 
probabilistic 
distributions are 
documented in 
Annex I to OECD 
GD 256. 
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10 Sequential testing 
strategy (STS) for 
sensitising potency 
classification based on 
in chemico and in vitro 
data (Kao Corporation) 
Hazard 
identification  
LLNA potency 
sub-
categorisation 
in 3 potency 
classes: non-
sensitisers (N), 
weak (W) 
(combined W 
and M 
sensitisers in 
the LLNA),  
strong (S) 
(combined S 
and E sentisers 
in the LLNA) 
1,3 OECD TG 442C (KE1) 
OECD TG 442E (KE3) 
Sequential Testing 
Strategy (TST) in 
which decision 
criteria are applied 
after each tier 
139 
(1O2 S) (37 NS) 
Against LLNA for 
binary 
classification: 
Accuracy 81 
Sensitivity 90 
Specificity 54 
 
Against LLNA 
potency 
classification: 
Strong (EC3<1% in 
the LLNA) and  
Weak (EC3≥1% in 
the LLNA):  
Accuracy  
Overall 69 
NS       54* 
Weak  78* 
Strong 66* 
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11 Integrated testing 
strategy (ITS) for 
sensitising potency 
classification based on 
in silico, in chemico, 
and in vitro data (Kao 
Corporation) 
Hazard 
identification  
LLNA potency 
sub-
categorisation 
in 3 potency 
classes: non-
sensitisers (N), 
weak (W) 
(combined W 
and M 
sensitisers in 
the LLNA),  
strong (S) 
(combined S 
and E sentisers 
in the LLNA) 
1,3 DEREK Nexus and OECD 
TG 442C (KE1) 
OECD TG 442E (KE3) 
Integrated Testing 
Strategy (ITS) based 
on the integration 
of input parameters 
converted into 
scores 
139 
(1O2 S) (37 NS) 
Against LLNA for 
binary 
classification: 
Accuracy 84 
Sensitivity 89 
Specificity 70 
 
Against LLNA 
potency 
classification 
Strong (EC3<1% in 
the LLNA) and  
Weak (EC3≥1% in 
the LLNA):  
Accuracy: 
Overall 71 
NS       70* 
Weak  78* 
Strong 52* 
 
12 DIP for skin allergy risk 
assessment (SARA) 
(Unilever) 
Potency 
prediction 
expressed as 
probability that 
a specific CD8+ 
T cell response 
will be induced 
following a 
given skin 
exposure to a 
direct-acting 
sensitising 
chemical 
1,3,4 Modified OECD TG 428 
to derive information on 
skin bioavailability 
kinetics and protein 
haptenation kinetics 
(KE1) 
Prediction of Class I 
MHC processing & 
presentation of 
haptenated skin protein 
by dendritic cells (DC) 
(KE3) 
Prediction of the extent 
of human naïve CD8+ T 
cell activation (KE4) 
 
Ordinary 
differential 
equation 
1 Not applicable  
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